GENTA INC DE/ Form 10-Q November 09, 2004

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### **FORM 10-Q**

(Mark One)

þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
	SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2004

OR

0	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
	SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_

Commission File Number 0-19635

#### GENTA INCORPORATED

(Exact name of Registrant as specified in its charter)

Delaware 33-0326866
(State or other jurisdiction of incorporation or organization) Identification Number)

Two Connell Drive
Berkeley Heights, NJ 07922

(Address of principal executive offices) (Zip Code)

(908) 286-9800

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes b

No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).

Yes b

No o

As of October 31, 2004, the registrant had 80,358,215 shares of common stock outstanding.

### Edgar Filing: GENTA INC DE/ - Form 10-Q

# Genta Incorporated INDEX TO FORM 10-Q

PART I.	FINANCIAL INFORMATION	<b>Page</b>
Item 1.	Financial Statements:	
	Consolidated Balance Sheets at September 30, 2004 and December 31, 2003	3
	Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2004 and 2003	4
	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2004 and 2003	5
	Notes to Consolidated Financial Statements	6
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	22
Item 4.	Controls and Procedures	23
PART II.	OTHER INFORMATION	
Item 1.	<u>Legal Proceedings</u>	24
Item 6.	Exhibits and Reports on Form 8-K	24
<u>SIGNATUI</u>	<u>RES</u>	26
CERTIFIC	TATIONS	
31.1 31.2 32.1	Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the	29 30
32.2	Sarbanes-Oxley Act of 2002 Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  2	31

## GENTA INCORPORATED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value data)

ASSETS	September 30, 2004 (Unaudited)		December 31, 2003	
Current assets:			_	
Cash and cash equivalents	\$	30,930	\$	25,153
Marketable securities (Note 3)		5,773		57,776
Accounts receivable - net		4,951		16,675
Notes receivable		200		200
Inventory (Note 4)		1,016		518
Prepaid expenses and other current assets		784		3,313
Total current assets		43,654		103,635
Property and equipment, net (Note 5)		3,382		4,917
Notes receivable (Note 10)		- /		3,542
Intangibles, net (Note 6)		430		863
Prepaid royalties		1,268		1,268
Other assets		1,631		450
Other dissects		1,031		150
Total assets	\$	50,365	\$	114,675
LIABILITIES AND STOCKHOLDERS DEFICIT/EQUITY				
Current liabilities:				
Accounts payable and accrued expenses	\$	18,073	\$	15,319
Notes payable		279		748
Deferred revenues, current portion		5,273		5,287
Short term debt (Note 7)		19,001		
Total current liabilities		42,626		21 254
Deferred revenues				21,354
		32,154		36,067
Convertible debt (Note 8)		10,000		10,000
Long term debt (Note 7)				35,000
Total liabilities		84,780		102,421
Commitments and contingencies (Note 11)				
Stockholders (deficit)/equity:				
Series A convertible preferred stock, \$.001 par value; 5,000 shares authorized, 10 shares and 261 shares issued and outstanding, liquidation value of \$485 and				
\$13,025 at September 30, 2004 and December 31, 2003 respectively				
Common stock, \$.001 par value; 155,000 shares authorized,				
80,358 and 75,927 shares issued and outstanding at September 30, 2004				
and December 31, 2003, respectively		80		76
Additional paid-in capital		336,189		335,713
Deferred financing costs		(48)		
Accumulated deficit		(370,567)		(323,299)

### Edgar Filing: GENTA INC DE/ - Form 10-Q

Deferred compensation	(52)		(261)
Accumulated other comprehensive (loss)/income	(17)		25
Total stockholders (deficit)/equity	(34,415)		12,254
Total liabilities and stockholders deficit/equity	\$ 50,365	\$	114,675
		_	
See accompanying notes to consolidated financial statements			
In A B			
3			

### GENTA INCORPORATED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended September 30,			Nine Months Ended September 30,				
(In thousands, except per share data)		2004		2003		2004	2003	
		(Unaudited)			(Unaudited)			
Revenues:								
Product sales - net	\$	87 261	\$	252	\$	711 783	\$	705
License fees and royalties				253				795
Development funding		1,049		1,043		3,145	_	3,130
Total revenues		1,397		1,296		4,639		3,925
Cost of goods sold		19				165		
Provision for excess inventory		693				693		
Total cost of goods sold		712				858		
Gross margin		685		1,296		3,781		3,925
Costs and expenses:  Research and development (including non-cash compensation expense of \$53 and \$52 for the three months ended September 30, 2004 and 2003, respectively and \$158 and \$157 for the nine months ended September 30, 2004 and 2003, respectively)  Selling, general and administrative (including non-cash compensation expense of \$11 and \$22 for the three months ended September 30, 2004 and 2003, respectively and \$50 and \$205 for the nine months ended September 30, 2004 and 2003, respectively)		20,643		21,061		61,940		54,733
Total costs and expenses - gross		25,364		30,370		86,168		75,136
Aventis reimbursement		(20,489)		(11,760)		(36,453)		(40,350)
Total costs and expenses - net		4,875		18,610		49,715	_	34,786
Loss on disposition of property and equipment		(1,254)		(2)		(1,254)		(2)
Other (expense)/income		(136)		151		(79)		677
Net loss	\$	(5,580)	\$	(17,165)	\$	(47,267)	\$	(30,186)
Net loss per basic and diluted share	\$	(0.07)	\$	(0.23)	\$	(0.60)	\$	(0.40)
Shares used in computing net loss per								
basic and diluted share		80,358		75,409		78,758		74,699

See accompanying notes to consolidated financial statements

# GENTA INCORPORATED CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine Months Ended September 30,

		_		
(In thousands)	2004	2003		
	(Unau	udited)		
Operating activities:	ф (47.0 <b>(</b> 7)	ф. (20.19 <i>C</i> )		
Net loss	\$ (47,267)	\$ (30,186)		
Items reflected in net loss not requiring cash:	2 222	1.666		
Depreciation and amortization	2,323	1,666		
Loss on disposition of property and equipment	1,254	2		
Non-cash reimbursement of research and development expense	(15,541)			
Provision for excess inventory	693	262		
Compensation expense related to stock options	208	362		
Changes in operating assets and liabilities:	10.550	(200)		
Accounts receivable	10,558	(399)		
Inventory	(1,191)			
Notes receivable	3,542			
Accounts payable, accrued expenses and other current liabilities	3,463	(21,270)		
Deferred revenue	(3,928)			
Other assets	1,349	(425)		
Net cash used in operating activities	(44,537)	(50,250)		
Investing activities:				
Purchase of marketable securities	(7,281)	(48,400)		
Maturities and sales of marketable securities	59,242	61,052		
Purchase of property and equipment	(1,767)	(2,615)		
Proceeds from disposition of property and equipment	157			
Payment to stockholders in conjunction with acquisition		(56)		
Net cash provided by investing activities	50,351	9,981		
Financing activities:		25,000		
Borrowings under long-term debt	410	25,000		
Borrowings under note payable	419	(100)		
Repayments of note payable	(888)	(490)		
Purchase of treasury stock		(303)		
Deferred financing costs	(48)			
Issuance of common stock upon exercise of warrants and options	480	2,397		
Net cash (used in)/provided by financing activities	(37)	26,604		
Increase/(decrease) in cash and cash equivalents	5,777	(13,665)		
Cash and cash equivalents at beginning of period	25,153	32,700		
		,. 00		